Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64651 | 0.96 | MAPT (0.82) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL20805871 | 0.94 | MAPT (0.68) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL20032702 | 0.92 | MAPT (0.70) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL7332647 | 0.91 | MAPT (0.68) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL13721594 | 0.91 | MAPT (0.68) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL14231641 | 0.88 | MAPT (0.74) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL14926517 | 0.88 | MAPT (0.80) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL7314671 | 0.88 | MAPT (0.74) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL223429 | 0.88 | MAPT (0.79) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL1951546 | 0.87 | MAPT (1.00) | MAPTRAB9ATDP1L3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | PBDC1, RCC1, PUF60 | MAPT 134/4885RAB9A 4403/4885TDP1 859/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | MAPT 3469/4885RAB9A 577/4885TDP1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.